(2-chloro-9-cyclopentyl-9H-purin-6-yl)(6-thiophen-2-yl-pyridin-3-ylmethyl)amine | 1448338-01-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: (2-chloro-9-cyclopentyl-9H-purin-6-yl)(6-thiophen-2-yl-pyridin-3-ylmethyl)amine
• 英文别名: (2-chloro-9-cyclopentyl-9H-purine-6-yl)(6-thiophen-2-ylpyridin-3-ylmethyl)amine；(2-chloro-9-cyclopentyl-9H-purine-6-yl)-(6-thiophen-2-yl-pyridin-3-ylmethyl)-amine；2-chloro-9-cyclopentyl-N-[(6-thiophen-2-ylpyridin-3-yl)methyl]purin-6-amine
• CAS: 1448338-01-9
• 化学式: C₂₀H₁₉ClN₆S
• 分子量: 410.93
• InChiKey: WZMMDPQPIFLOOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  96.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2-chloro-9-cyclopentyl-9H-purin-6-yl)(6-thiophen-2-yl-pyridin-3-ylmethyl)amine 、 trans-1,4-Diaminocyclohexane 反应 3.0h， 以88%的产率得到N²-(4-aminocyclohexyl)-9-cyclopentyl-N⁶-(6-thiophen-2-yl-pyridin-3-ylmethyl)-9H-purine-2,6-diamine
  参考文献：
  名称：

  2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS

  摘要：

  本发明涉及新颖的2-取代-6-双芳基甲氨基-9-环戊基-9H-嘌呤衍生物，显示出作为肝细胞癌生长和血管生成特异性抑制剂的活性。本发明进一步包括含有这些2-取代-6-双芳基甲氨基-9-环戊基嘌呤的药物组合物。

  公开号：

  US20150368248A1
• 作为产物：
  描述：

  2,6-二氯嘌呤 在 偶氮二甲酸二异丙酯 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 丙醇 、 甲苯 为溶剂， 反应 18.0h， 生成 (2-chloro-9-cyclopentyl-9H-purin-6-yl)(6-thiophen-2-yl-pyridin-3-ylmethyl)amine
  参考文献：
  名称：

  2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS

  摘要：

  本发明涉及新颖的2-取代-6-双芳基甲氨基-9-环戊基-9H-嘌呤衍生物，显示出作为肝细胞癌生长和血管生成特异性抑制剂的活性。本发明进一步包括含有这些2-取代-6-双芳基甲氨基-9-环戊基嘌呤的药物组合物。

  公开号：

  US20150368248A1

文献信息

• 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS
  申请人：UNIVERZITA PALACKEHO V OLOMOUCI

  公开号：US20150368248A1

  公开（公告）日：2015-12-24

  This invention relates to novel 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, showing activity as specific inhibitors of growth and angiogenesis of hepatocellular carcinoma. The invention further includes pharmaceutical compositions containing the 2-substituted-6-biarylmethylamino-9-cyclopentylpurines.

  本发明涉及新颖的2-取代-6-双芳基甲氨基-9-环戊基-9H-嘌呤衍生物，显示出作为肝细胞癌生长和血管生成特异性抑制剂的活性。本发明进一步包括含有这些2-取代-6-双芳基甲氨基-9-环戊基嘌呤的药物组合物。
• N2-SUBSTITUTED-N6-(6-ARYL-PYRIDINE-3-YLMETHYL)-9-CYCLOPENTYL-9H-PURINE-2,6-DIAMINE DERIVATIVES AS TUMOR SUPPRESSOR P53 ACTIVATORS FOR INHIBITING ANGIOGENESIS AND FOR TREATING CANCER
  申请人：Univerzita Palackeho v Olomouci

  公开号：EP2953951B1

  公开（公告）日：2017-05-03
• [EN] 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS<br/>[FR] DÉRIVÉS DE 6-BIARYLMÉTHYLAMINO-9-CYCLOPENTYL-9H-PURINE 2-SUBSTITUÉE, LEUR UTILISATION COMME MÉDICAMENTS ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：UNIV PALACKEHO

  公开号：WO2014121764A2

  公开（公告）日：2014-08-14

  This invention relates to novel 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, showing activity as specific inhibitors of growth and angiogenesis of hepatocellular carcinoma. The invention further includes pharmaceutical compositions containing the 2-substituted-6-biarylmethylamino-9-cyclopentylpurines.
• A Novel Series of Highly Potent 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase Inhibitors
  作者：Tomáš Gucký、Radek Jorda、Marek Zatloukal、Václav Bazgier、Karel Berka、Eva Řezníčková、Tibor Béres、Miroslav Strnad、Vladimír Kryštof

  DOI：10.1021/jm4006884

  日期：2013.8.8

  The inhibition of overactive CDKs during cancer remains an important strategy in cancer drug development. We synthesized and screened a novel series of 2-substituted-6-biarylmethylamino-9-cyclopentylpurine derivatives for improved CDK inhibitory activity and antiproliferative effects. One of the most potent compounds, 6b, exhibited strong cytotoxicity in the human melanoma cell line G361 that correlated with robust CDK1 and CDK2 inhibition and caspase activation. In silico modeling of 6b in the active site of CDK2 revealed a high interaction energy, which we believe is due to the 6-heterobiarylmethylamino substitution of the purine moiety.